Dr. Leblond Discusses Treatment After Relapse in CLL

Veronique Leblond, MD
Published: Tuesday, May 02, 2017



Veronique Leblond, MD, head of the Department of Hematology, Pitié Salpêtrière Hospital, Paris, France, discusses the treatment of patients with chronic lymphocytic leukemia (CLL) who have relapsed after initial treatment.

For patients who relapse within 3 years after discontinuation of chemotherapy, BCR inhibitors or venetoclax (Venclexta) can be used.

Questions remain for patients who have late relapses, says Leblond. For these patients with relapses 4 or 5 years after initial therapy, BCR inhibitors can be used—but combinations of immunotherapy, chemotherapy, and BCR inhibitors also hold promise.
 
SELECTED
LANGUAGE


Veronique Leblond, MD, head of the Department of Hematology, Pitié Salpêtrière Hospital, Paris, France, discusses the treatment of patients with chronic lymphocytic leukemia (CLL) who have relapsed after initial treatment.

For patients who relapse within 3 years after discontinuation of chemotherapy, BCR inhibitors or venetoclax (Venclexta) can be used.

Questions remain for patients who have late relapses, says Leblond. For these patients with relapses 4 or 5 years after initial therapy, BCR inhibitors can be used—but combinations of immunotherapy, chemotherapy, and BCR inhibitors also hold promise.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x